Morgan Stanley Editas Medicine, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,420,683 shares of EDIT stock, worth $3.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,420,683

Previous 2,658,921 46.57%

Holding current value

$3.25 Million

Previous $3.08 Million 1.33%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	SELL	$0.98 - $2.35 $1.21 Million - $2.91 Million	-1,238,238 Reduced 46.57%	1,420,683 $3.13 Million
Q1 2025 May 15, 2025	BUY	$1.14 - $3.2 $1.27 Million - $3.58 Million	1,118,298 Added 72.59%	2,658,921 $3.08 Million
Q4 2024 Feb 14, 2025	BUY	$1.2 - $3.76 $280,113 - $877,689	233,428 Added 17.86%	1,540,623 $1.96 Million
Q3 2024 May 14, 2025	BUY	$3.39 - $5.96 $1.32 Million - $2.32 Million	388,961 Added 42.36%	1,307,195 $4.46 Million
Q3 2024 Nov 14, 2024	BUY	$3.39 - $5.96 $1.32 Million - $2.32 Million	388,961 Added 42.36%	1,307,195 $4.46 Million
Q2 2024 May 14, 2025	SELL	$4.67 - $7.28 $2.91 Million - $4.53 Million	-622,389 Reduced 40.4%	918,234 $4.29 Million
Q2 2024 Oct 17, 2024	SELL	$4.67 - $7.28 $4.04 Million - $6.3 Million	-865,498 Reduced 48.52%	918,234 $4.29 Million
Q2 2024 Aug 14, 2024	SELL	$4.67 - $7.28 $4.04 Million - $6.3 Million	-865,498 Reduced 48.52%	918,234 $4.29 Million
Q1 2024 Oct 17, 2024	BUY	$7.03 - $11.07 $6.08 Million - $9.58 Million	865,498 Added 94.26%	1,783,732 $13.2 Million
Q1 2024 Aug 16, 2024	BUY	$7.03 - $11.07 $3.65 Million - $5.75 Million	519,197 Added 41.06%	1,783,732 $13.2 Million
Q1 2024 May 15, 2024	BUY	$7.03 - $11.07 $3.65 Million - $5.75 Million	519,197 Added 41.06%	1,783,732 $13.2 Million
Q4 2023 Aug 16, 2024	BUY	$6.25 - $11.11 $2.16 Million - $3.85 Million	346,301 Added 37.71%	1,264,535 $12.8 Million
Q4 2023 Feb 13, 2024	SELL	$6.25 - $11.11 $438,512 - $779,499	-70,162 Reduced 5.26%	1,264,535 $12.8 Million
Q3 2023 Nov 15, 2023	SELL	$6.92 - $9.31 $2.56 Million - $3.45 Million	-370,261 Reduced 21.72%	1,334,697 $10.4 Million
Q2 2023 Aug 14, 2023	BUY	$6.36 - $11.47 $5.27 Million - $9.5 Million	828,521 Added 94.53%	1,704,958 $14 Million
Q1 2023 May 15, 2023	SELL	$7.03 - $11.53 $48,317 - $79,245	-6,873 Reduced 0.78%	876,437 $6.35 Million
Q4 2022 Feb 14, 2023	SELL	$8.32 - $13.21 $186,584 - $296,247	-22,426 Reduced 2.48%	883,310 $7.83 Million
Q3 2022 Nov 14, 2022	SELL	$12.16 - $19.42 $2 Million - $3.2 Million	-164,717 Reduced 15.39%	905,736 $11.1 Million
Q2 2022 Oct 27, 2022	SELL	$9.99 - $21.35 $512,656 - $1.1 Million	-51,317 Reduced 4.57%	1,070,453 $12.7 Million
Q2 2022 Aug 15, 2022	SELL	$9.99 - $21.35 $512,656 - $1.1 Million	-51,317 Reduced 4.57%	1,070,453 $12.7 Million
Q1 2022 Oct 27, 2022	BUY	$14.08 - $27.63 $722,543 - $1.42 Million	51,317 Added 4.79%	1,121,770 $21.3 Million
Q1 2022 May 13, 2022	BUY	$14.08 - $27.63 $2.18 Million - $4.28 Million	155,072 Added 16.04%	1,121,770 $21.3 Million
Q4 2021 Feb 14, 2022	BUY	$26.55 - $40.57 $1.42 Million - $2.18 Million	53,650 Added 5.88%	966,698 $25.7 Million
Q3 2021 Nov 15, 2021	BUY	$39.27 - $72.94 $35.9 Million - $66.6 Million	913,048 New	913,048 $37.5 Million

Others Institutions Holding EDIT

# of Institutions

220

Shares Held

47M

Call Options Held

365K

Put Options Held

354K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $157M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account